Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer – Samuel A. Funt

In this UroToday discussion between Alicia Morgans and Samuel Funt, they discuss Samuel Funt’s recent phase 2 trial evaluating the use of atezolizumab, with gemcitabine and cisplatin, as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). The conversation begins with background on the study, beginning with Dr. Funt’s description of neoadjuvant cisplatin-based chemotherapy as the…

Read the full article here

Related Articles